Mark A. Velleca
CIK 1706847 · PRESIDENT & CEO · last filed 2026-01-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$254.0K
Companies
2
Total Filings
49
Lifetime Open-Market Net
-$8.88M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BDTX | PRESIDENT & CEO | 121,522 | $2.09 | $254.0K | $0 | 13 | 2026-01-23 |
| G1 Therapeutics, Inc. (GTHX) Delisted | Director | 173,286 | $7.15 | $1.24M | -$8.88M | 32 | 2023-08-10 |
Recent Filings · Page 3 of 5
49 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-02-08 | G1 Therapeutics, Inc. (GTHX) Delisted | Exer (M) | +15,000 | $5.8K | EDGAR |
| 2021-11-10 | G1 Therapeutics, Inc. (GTHX) Delisted | Exer (M) | +40,000 | $15.6K | EDGAR |
| 2021-08-11 | BDTX | Grant (A) | — | $0 | EDGAR |
| 2021-07-15 | G1 Therapeutics, Inc. (GTHX) Delisted | Mixed | — | -$558.6K | EDGAR |
| 2021-06-17 | G1 Therapeutics, Inc. (GTHX) Delisted | Mixed | — | -$647.3K | EDGAR |
| 2021-05-25 | G1 Therapeutics, Inc. (GTHX) Delisted | Exer (M) | +20,000 | $7.8K | EDGAR |
| 2021-05-13 | G1 Therapeutics, Inc. (GTHX) Delisted | Mixed | — | -$585.4K | EDGAR |
| 2021-04-15 | G1 Therapeutics, Inc. (GTHX) Delisted | Mixed | — | -$722.1K | EDGAR |
| 2021-02-18 | G1 Therapeutics, Inc. (GTHX) Delisted | Mixed | — | -$809.8K | EDGAR |
| 2021-01-21 | G1 Therapeutics, Inc. (GTHX) Delisted | Mixed | +4,000 | -$517.1K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.